Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011242 · ClinicalTrials.gov registry record
DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 47
- Enrollment target
NCT03011242: Completed study, sponsored by University of Rochester.
NCT03011242 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03011242 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
The Investigators will examine if DC-STAMP can serve as an early marker of TNFi response in PsA. Identification of such a biomarker would permit rapid transition to a new agent, a major treatment advance. TNFi are the most effective therapies in PsA, however, methotrexate is frequently initiated early in the disease course based on its significantly lower cost. Unfortunately, the efficacy of MTX has not been supported in clinical trials and up to 40% of patients do not respond to TNFi therapy. Moreover, valid biomarkers to predict MTX or TNFi responses are currently unavailable. This study may also provide the first data on the comparative efficacy of MTX and TNFi using clinical, Ultrasound (US) and biomarker outcomes.
Primary Outcome
The Investigators will analyze the change in DC-STAMP expression from baseline to 2 weeks using flow cytometry.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2021-06-30 |
What the finished NCT03011242 record still lists
NCT03011242 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03011242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03011242 about?
NCT03011242 is a clinical study titled "DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA". The Investigators will examine if DC-STAMP can serve as an early marker of TNFi response in PsA. Identification of such a biomarker would permit rapid transition to a new agent, a major treatment advance. TNFi are the most effective therapies in PsA, however, methotrexate is frequently initiated ear...
What is the current status of trial NCT03011242?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-01-11. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT03011242?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI